Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Regeneron Pharmaceuticals REGN Get Free Report has outperformed the market over the past 15 years by 12.37% on an annualized ...
REGN Shareholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
Shares of Regeneron Pharmaceuticals Inc. slid 3.61% to $665.46 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.03% to 6,068.
Cytokinetics Names Robert E. Landry to Board of Directors
Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential CommercializationSOUTH SAN FRANCISCO, Calif., ...
Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma
Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
The stock's fall snapped a three-day winning streak.
Nasdaq18d
Beyond The Numbers: 18 Analysts Discuss Regeneron Pharmaceuticals Stock
During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN), revealing diverse outlooks from bullish to bearish. The table below offers a ...
Longview News-Journal19d
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
announces the filing of a class action lawsuit on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates ...
The Victoria Advocate19d
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Jan. 27, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc ...